Canton Hathaway LLC Takes $79,000 Position in Astera Labs, Inc. (NASDAQ:ALAB)

Canton Hathaway LLC bought a new position in shares of Astera Labs, Inc. (NASDAQ:ALABFree Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,500 shares of the company’s stock, valued at approximately $79,000.

Several other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. bought a new position in Astera Labs during the 1st quarter worth $127,268,000. Westfield Capital Management Co. LP acquired a new stake in Astera Labs in the 3rd quarter worth about $52,049,000. Price T Rowe Associates Inc. MD bought a new stake in Astera Labs in the 1st quarter valued at about $44,514,000. TimesSquare Capital Management LLC grew its position in shares of Astera Labs by 158,424.1% during the 3rd quarter. TimesSquare Capital Management LLC now owns 321,804 shares of the company’s stock worth $16,859,000 after purchasing an additional 321,601 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of Astera Labs during the first quarter worth approximately $20,025,000.

Astera Labs Stock Performance

Shares of NASDAQ ALAB opened at $106.99 on Monday. The firm has a 50 day moving average price of $69.60 and a two-hundred day moving average price of $59.79. Astera Labs, Inc. has a 52-week low of $36.22 and a 52-week high of $109.11.

Astera Labs (NASDAQ:ALABGet Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.17 by $0.06. The business had revenue of $113.10 million during the quarter, compared to the consensus estimate of $97.50 million. Astera Labs had a negative return on equity of 15.57% and a negative net margin of 30.69%. Astera Labs’s revenue was up 47.1% compared to the same quarter last year. On average, equities analysts forecast that Astera Labs, Inc. will post -0.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ALAB shares. Evercore ISI reduced their price target on Astera Labs from $98.00 to $80.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Morgan Stanley boosted their price objective on shares of Astera Labs from $74.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Barclays boosted their price target on Astera Labs from $70.00 to $87.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Stifel Nicolaus raised their price objective on Astera Labs from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, Citigroup assumed coverage on Astera Labs in a research note on Monday, November 18th. They set a “buy” rating and a $120.00 target price for the company. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $94.67.

Check Out Our Latest Report on Astera Labs

Insider Activity

In other news, General Counsel Philip Mazzara sold 2,513 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $90.81, for a total value of $228,205.53. Following the transaction, the general counsel now owns 248,745 shares in the company, valued at approximately $22,588,533.45. The trade was a 1.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jack R. Lazar sold 3,000 shares of the stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $61.69, for a total transaction of $185,070.00. Following the sale, the director now owns 137,000 shares of the company’s stock, valued at approximately $8,451,530. This trade represents a 2.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,565,576 shares of company stock valued at $129,835,552.

Astera Labs Company Profile

(Free Report)

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

Further Reading

Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALABFree Report).

Institutional Ownership by Quarter for Astera Labs (NASDAQ:ALAB)

Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.